

Allure

Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids in Subjects with Active Class III or IV Lupus Nephritis

Study summary:

- Patients with active lupus nephritis
- Patients receive Mycophenolate Mofetil (MMF) plus Abatacept or placebo for 2 years
- Medications: Abatacept infusion the vein and MMF pills

Inclusion criteria

- High amount of protein in urine
- Renal biopsy with 12 months; class 3 or 4
- Active renal disease (blood in urine)

Exclusion criteria:

- Prior use of Abatacept
- If on MMF for more than 3 months for the current lupus nephritis flare

Contact:

UT Southwestern Medical Center
Rheumatology
Azza Mutwally- (214) 648-7219
Rasha Babikir- (214) 648- 9111
www.MyLupusResearchStudy.com